Clinical Trial Update: Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

View source ↗

Summary

A completed trial comparing combination inhaled therapy fluticasone propionate-salmeterol (250/50 mcg) versus anticholinergic bronchodilators in COPD patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone propionate-salmeterol 250/50 mcg inhalation powder (Fluticasone propionate; Salmeterol xinafoate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Status: COMPLETED | Results posted: 2011-05-20